Chemomab Therapeutics Ltd - ADR

NEW
NAS:CMMB (Israel)   ADR
$ 1.285 -0.055 (-4.1%) 01:55 PM EST
At Loss
P/B:
1.78
Market Cap:
$ 24.23M
Enterprise V:
$ 11.31M
Volume:
58.37K
Avg Vol (2M):
131.33K
Warning! GuruFocus detected 1 Severe warning sign with CMMB. Try a 7-Day Free Trial to check it out.
Trade In:
What is a stock summary page? Click here for an overview.
Volume:
58.37K
Market Cap $:
24.23M
At Loss
Avg Vol (2M):
131.33K
Enterprise Value $:
11.31M
PB Ratio:
1.78
Website SEC Filings Stock PDF
Dataset
Financial Download GuruFocus Premium Icon Manual of Stocksâ„¢

Business Description

Chemomab Therapeutics Ltd
NAICS : 541714 SIC : 8731
ISIN : US16385C1045
https://www.chemomab.com
Kiryat Atidim, Building 7, Tel Aviv, ISR, 6158002

Share Class Description:

CMMB: ADR
Compare
Compare
OVIDPULMCVMMLECCARACDIOTENXNRSNCLGNIGCVRTXASX:CSLREGNXKRX:207940XBRU:ARGXALNYXBRU:UCBONCBNTXXKRX:068270
Traded in other countries / regions
CMMB.USA2QV0.Germany
IPO Date
2021-03-17
Description
Chemomab Therapeutics Ltd is a clinical-stage biotech company, focusing on the discovery and development of therapeutics for fibrosis-related diseases with large unmet needs. The company's candidate, CM-101, is a monoclonal antibody that targets CCL24 and was shown to interfere with the underlying biology of liver, skin, and lung fibrosis using a novel and differentiated mechanism of action. CM-101 has demonstrated the potential to treat multiple severe and life-threatening fibrotic and inflammatory diseases. It is advancing three Phase 2 clinical trials in parallel for CM-101, treating rare fibrotic conditions.

Financial Strength

8/10
Name Current Vs Industry Vs History
Cash-To-Debt 44.03
Equity-to-Asset 0.8
Debt-to-Equity 0.02
Debt-to-EBITDA -0.02
Interest Coverage N/A
N/A
N/A
Piotroski F-Score 2/9
0
1
2
3
4
5
6
7
8
9
WACC vs ROIC
WACC
ROIC

Growth Rank

Name Current Vs Industry Vs History
3-Year EBITDA Growth Rate 11.7
3-Year EPS without NRI Growth Rate 13.4
3-Year FCF Growth Rate 11
3-Year Book Growth Rate -48.9
Future 3-5Y EPS without NRI Growth Rate Estimate 18.68

Momentum Rank

6/10
Name Current Vs Industry Vs History
5-Day RSI 83.26
9-Day RSI 69.21
14-Day RSI 59.1
3-1 Month Momentum % -45.93
6-1 Month Momentum % -26.14
12-1 Month Momentum % 76.59

Liquidity Ratio

Name Current Vs Industry Vs History
Current Ratio 4.98
Quick Ratio 4.98
Cash Ratio 4.43

Dividend & Buy Back

Name Current Vs Industry Vs History
3-Year Average Share Buyback Ratio -18.2
Shareholder Yield % -40.42

Profitability Rank

1/10
Name Current Vs Industry Vs History
ROE % -99.37
ROA % -75.33
ROIC % -793.27
3-Year ROIIC % 464.19
ROC (Joel Greenblatt) % -2401.27
ROCE % -103.14

GF Value Rank

Name Current Vs Industry Vs History
PB Ratio 1.78
Price-to-Tangible-Book 1.78
EV-to-EBIT -0.77
EV-to-EBITDA -0.77
EV-to-FCF -0.7
Price-to-Net-Current-Asset-Value 1.92
Price-to-Net-Cash 2.25
Earnings Yield (Greenblatt) % -129.87
FCF Yield % -63.5

Financials (Next Earnings Date:2025-05-09 Est.)

CMMB's 30-Y Financials
AAPL
Income Statement Breakdown FY
Not Enough Data
AAPL
Balance Sheet Breakdown
Not Enough Data
AAPL
Cashflow Statement Breakdown
Not Enough Data

Operating Revenue by Business Segment

Operating Revenue by Geographic Region

Historical Operating Revenue by Business Segment

Historical Operating Revenue by Geographic Region

5-Step DuPont Analysis as of
Not Enough Data

Guru Trades

See Details
To

Insider Trades

See Details
To

Gurus Latest Trades with NAS:CMMB

No Available Data

Peter Lynch Chart

Y-axis scale:
Interactive Chart
To

Performance

Dividend
Log
Bar
To

Annualized Return %  

Symbol
1 Week
1 Month
3 Months
6 Months
YTD
1 Year
3 Years
5 Years
10 Years

Total Annual Return %  

Symbol
2025
2024
2023
2022
2021
2020
2019
2018
2017
2016

Chemomab Therapeutics Ltd Executives

Details

GF Value

CMMB

Valuation Chart

Year:

Analyst Estimate

Key Statistics

Name Value
Revenue (TTM) (Mil $)
EPS (TTM) ($) -0.9
Beta 0.53
3-Year Sharpe Ratio -0.21
3-Year Sortino Ratio -0.34
Volatility % 112.87
14-Day RSI 59.1
14-Day ATR ($) 0.11785
20-Day SMA ($) 1.12436
12-1 Month Momentum % 76.59
52-Week Range ($) 0.603 - 2.55
Shares Outstanding (Mil) 18.86

Piotroski F-Score Details

Year:
Component Result
Piotroski F-Score 2
Positive ROA
Positive CFROA
Higher ROA yoy
CFROA > ROA
Lower Leverage yoy
Higher Current Ratio yoy
Less Shares Outstanding yoy
Higher Gross Margin yoy
Higher Asset Turnover yoy

Chemomab Therapeutics Ltd Filings

Filing Date Document Date Form
No Filing Data

Chemomab Therapeutics Ltd Stock Events

Financials Calendars
Event Date Price ($)
No Event Data

Chemomab Therapeutics Ltd Frequently Asked Questions

What is Chemomab Therapeutics Ltd(CMMB)'s stock price today?
The current price of CMMB is $1.29. The 52 week high of CMMB is $2.55 and 52 week low is $0.60.
When is next earnings date of Chemomab Therapeutics Ltd(CMMB)?
The next earnings date of Chemomab Therapeutics Ltd(CMMB) is 2025-05-09 Est..
Does Chemomab Therapeutics Ltd(CMMB) pay dividends? If so, how much?
Chemomab Therapeutics Ltd(CMMB) does not pay dividend.

Guru Commentaries on NAS:CMMB

No articles.

Press Release

Subject Date
No Press Release

Headlines

See More
  • 1
No news.
  • 1
Research Tools
All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board
Product
Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App 中文
Education
Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation
Company
About GuruFocus Career Contact Us Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program
Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey
Follow Us
download GuruFocus on Apple store download GuruFocus on Google Play
Disclaimers
GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.
© 2004-2025 GuruFocus.com, LLC. All Rights Reserved.